Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases - PubMed (original) (raw)
doi: 10.1016/j.ccr.2004.10.011.
Sergey V Kozin, Ricky T Tong, Sung-Suk Chae, Michael F Booth, Igor Garkavtsev, Lei Xu, Daniel J Hicklin, Dai Fukumura, Emmanuelle di Tomaso, Lance L Munn, Rakesh K Jain
Affiliations
- PMID: 15607960
- DOI: 10.1016/j.ccr.2004.10.011
Free article
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases
Frank Winkler et al. Cancer Cell. 2004 Dec.
Free article
Abstract
The recent landmark Phase III clinical trial with a VEGF-specific antibody suggests that antiangiogenic therapy must be combined with cytotoxic therapy for the treatment of solid tumors. However, there are no guidelines for optimal scheduling of these therapies. Here we show that VEGFR2 blockade creates a "normalization window"--a period during which combined radiation therapy gives the best outcome. This window is characterized by an increase in tumor oxygenation, which is known to enhance radiation response. During the normalization window, but not before or after it, VEGFR2 blockade increases pericyte coverage of brain tumor vessels via upregulation of Ang1 and degrades their pathologically thick basement membrane via MMP activation.
Comment in
- Antiangiogenic therapy: creating a unique "window" of opportunity.
Lin MI, Sessa WC. Lin MI, et al. Cancer Cell. 2004 Dec;6(6):529-31. doi: 10.1016/j.ccr.2004.12.003. Cancer Cell. 2004. PMID: 15607955
Similar articles
- Antiangiogenic therapy: creating a unique "window" of opportunity.
Lin MI, Sessa WC. Lin MI, et al. Cancer Cell. 2004 Dec;6(6):529-31. doi: 10.1016/j.ccr.2004.12.003. Cancer Cell. 2004. PMID: 15607955 - Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM. Mancuso MR, et al. J Clin Invest. 2006 Oct;116(10):2610-21. doi: 10.1172/JCI24612. J Clin Invest. 2006. PMID: 17016557 Free PMC article. - Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
Li J, Huang S, Armstrong EA, Fowler JF, Harari PM. Li J, et al. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1477-85. doi: 10.1016/j.ijrobp.2005.04.028. Int J Radiat Oncol Biol Phys. 2005. PMID: 16029810 - Anti-angiogenic treatment strategies for malignant brain tumors.
Kirsch M, Schackert G, Black PM. Kirsch M, et al. J Neurooncol. 2000 Oct-Nov;50(1-2):149-63. doi: 10.1023/a:1006487412567. J Neurooncol. 2000. PMID: 11245274 Review. - Novel anti-angiogenic therapies for malignant gliomas.
Norden AD, Drappatz J, Wen PY. Norden AD, et al. Lancet Neurol. 2008 Dec;7(12):1152-60. doi: 10.1016/S1474-4422(08)70260-6. Lancet Neurol. 2008. PMID: 19007739 Review.
Cited by
- Targeting the tumour vasculature: from vessel destruction to promotion.
Guelfi S, Hodivala-Dilke K, Bergers G. Guelfi S, et al. Nat Rev Cancer. 2024 Aug 29. doi: 10.1038/s41568-024-00736-0. Online ahead of print. Nat Rev Cancer. 2024. PMID: 39210063 Review. - Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment.
Ezaki T, Tanaka T, Tamura R, Ohara K, Yamamoto Y, Takei J, Morimoto Y, Imai R, Kuranai Y, Akasaki Y, Toda M, Murayama Y, Miyake K, Sasaki H. Ezaki T, et al. Brain Tumor Pathol. 2024 Apr;41(2):61-72. doi: 10.1007/s10014-024-00481-0. Epub 2024 Apr 15. Brain Tumor Pathol. 2024. PMID: 38619734 Free PMC article. - A bibliometric analysis of the research landscape on vascular normalization in cancer.
Xie H, Wang S, Niu D, Yang C, Bai H, Lei T, Liu H. Xie H, et al. Heliyon. 2024 Apr 3;10(7):e29199. doi: 10.1016/j.heliyon.2024.e29199. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38617971 Free PMC article. - Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials.
Kuo HY, Khan KA, Kerbel RS. Kuo HY, et al. Nat Rev Clin Oncol. 2024 Jun;21(6):468-482. doi: 10.1038/s41571-024-00886-y. Epub 2024 Apr 10. Nat Rev Clin Oncol. 2024. PMID: 38600370 Review. - Aberrant tumor vasculature. Facts and pitfalls.
Ribatti D. Ribatti D. Front Pharmacol. 2024 Mar 21;15:1384721. doi: 10.3389/fphar.2024.1384721. eCollection 2024. Front Pharmacol. 2024. PMID: 38576482 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous